Abstract
The global HIV epidemic continues to grow in certain regions while contracting in others, necessitating a broadened research agenda, including clinical pharmacology of tuberculosis, hepatitis, malaria, and immune activation/inflammation, underscoring the need for a coordinated quality assurance approach. A comprehensive program has been developed and implemented by the University at Buffalo HIV Clinical Pharmacology Quality Assurance and Quality Control Program, funded by the National Institutes of Health. Clinical Pharmacology & Therapeutics (2013); 93 6, 479-482. doi:10.1038/clpt.2013.62
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
